Highlights BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Market Closed - Hong Kong S.E. Other stock markets 09:08:20 14/05/2024 BST			5-day change	1st Jan Change
98.85 ^HKD	+1.96%		+1.38%	-10.22%

05-09	Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	MT
05-08	Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	05-09	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	05-08	MT
BeiGene's Q1 Loss Narrows as Revenue Rises	05-08	MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M	05-08	MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	05-08	CI
Amgen Posts Higher 1Q Revenue, Swings to Loss	05-02	DJ
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	04-23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	04-23	MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	04-23	CI
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	04-10	MT
Beigene Shrinks Loss by 56% in 2023	03-29	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	03-22	MT
Beigene's Esophageal Cancer Drug Gets US FDA Nod	03-15	MT
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	03-14	MT
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	03-14	CI
US FDA approves BeiGene's esophageal cancer therapy	03-14	RE
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership	03-13	MT
BeiGene Shares Rise on First Dosing of Brukinsa	03-13	DJ
BeiGene Gets FDA's Accelerated Approval for Follicular Lymphoma Treatment	03-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Highlights

Filters